Evaxion

Evaxion’s clinically validated AI-Immunology platform is used for target discovery, drug design, and development in cancer and infectious diseases.

Evaxion’s pipeline includes vaccine and immunotherapy candidates for cancer and infectious diseases, supported by its scalable AI-Immunology platform and predictive models.

Evaxion R&D advances vaccine immunotherapies for cancer and infectious diseases, spanning AI immuno-informatics, laboratories, translational medicine, clinical development, and manufacturing.

The global SARS-CoV-2 pandemic caused significant social and economic disruption worldwide, despite highly effective vaccines being developed at an unprecedented speed.

Neoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines.

Tumor mutation-derived neoantigens are considered promising targets for cancer immunotherapy.

Discovery collaboration for a vaccine against Gonorrhea

Evaxion received grant funding for designing a new polio vaccine.

Clinical trial supply agreement for personalized cancer vaccine, EVX-01

License agreement for EVX-B3

Dr. Helen Tayton-Martin joined Evaxion as Chief Executive Officer in November 2025. She holds a Ph.D. in molecular immunology and an MBA from London Business School and previously co-founded Adaptimmune, a cancer-focused biotech company, where she served as Chief Operating Officer and later Chief Business & Strategy Officer.

Jens Bitsch-Nørhave is Corporate Vice President and Global Head of Corporate Development at Hengrui Pharmaceuticals, overseeing strategy, business development, licensing, M&A, and alliance management. He holds an MSc and Ph.D. in neuropharmacology from the University of Copenhagen and an Executive MBA in Technology.

Lars worked for 35 years at PwC in Denmark, including four years as Chairman of the Board, advising major Danish pharmaceutical and biotech companies on management remuneration. He currently serves on the boards of several companies.

Lars Staal Wegner earned his M.D. from the University of Southern Denmark and serves as VP of Business Development at Hengrui Pharmaceuticals, a global pharmaceutical company. He specializes in artificial intelligence, biotechnology finance, business development, and research.

Evaxion partners to develop vaccines for cancer and infectious diseases and accelerates vaccine target discovery using its AI-Immunology platform.

AI-Immunology enables novel personalized and precision vaccines for cancer and infectious diseases, combining in-house AI building blocks into tailored prediction models for immune health.

Evaxion’s privacy policy explains how personal data collected via its website is handled and protected.